Acceleration programmes under Adamed’s patronage
We search for innovative solutions
Comprehensive support across
all stages of business development
Access to unique laboratory infrastructure that can be used for manufacturing and performing research studies ranging from new molecules to advanced animal models
Market data, business model validation, support in creating a sales strategy, and consultations with opinion leaders in selected fields of medicine
Investment in selected teams and their technologies.
Adamed is also a patron of competitions aimed at identifying and promoting the most promising start-ups.We have been involved in the following projects: Orzeł Innowacji Startup, CEE Startup Challange, CEE Scaleup Challenge, MedTrends - Top Trends, Startup Challenge as part of the European Startup Days, and Start-Up-Med as part of the Health Challenges Congress.
If you are working on a technology that addresses an unmet medical need or inefficiency in the healthcare system, and are seeking both financing for its further development and an investor with industry know-how, a network of contacts, and access to distribution channels, please contact Adamed Technology Sp. z o.o: email@example.com.
We work with the Foundation for Technology Entrepreneurship (FPT), which organises the MIT Enterprise Forum CEE accelerator as part of a global network of MIT Enterprise Forums affiliated with the world’s top technology university, Massachusetts Institute of Technology. The programme aims to support the development of the most innovative start-ups in Central and Eastern Europe by combining their potential with the knowledge and resources of leading enterprises and the experience of Polish and international mentors. Adamed has been a partner in the programme since its first edition.
In the previous three editions of the programme, Adamed supported Waw.ac, the Warsaw Technology Accelerator, an initiative focused on accelerating the growth of teams from scientific centres whose key assets are the results of research studies. We have also been engaged in the Startup HUB accelerator for young companies from the CEE region, the Alfc.ac pre-acceleration programme for researchers, and the BioMed PFR Academy, an educational project for innovative pharmaceutical and medical companies.
We have supported the growth of many companies working on a variety of technologies, including a prostate biopsy needle with a special coating to minimise the risk of infections, an implant emitting alternating electric fields for future application in the treatment of the most malignant brain cancers, a medical device supporting prostatitis therapy, a solution based on blockchain technology promoting blood donation, and a new medicine for inflammatory bowel disease which uses nanocarriers.
Adamed stands for professionalism and is open to sharing its expertise and experience. Throughout our collaboration we received extensive support for virtually every aspect of our pharmaceuticals supply system, from optimisation of the formulation and defining the scope of biological studies to market analysis and protection of intellectual property.
Vice-President of Sovigo Sp. z o.o.
Adamed has proved itself as a knowledgeable and professional partner who is flexible and open to new ideas. In over a year of joint initiatives, Adamed’s experts helped us find a global distributorand engaged their representatives to promote MST simulators among the medical community in Poland.This gave us the motivation we needed to work relentlessly on our operational plan and strategic development of our business, which translated into positive sales results.
CEO, Medical Simulation Technologies Sp. z o.o.
Support from Adamed’s expertsempowered us to make modifications to our initial research and development strategy, saving us a lot of time and money. Their dedicated experts were always very friendly and professional. We are especially grateful for networking, which allowed us to establish new contactsthat have been incredibly helpful in further stages of product development.
General Manager, DEBN Sp. z o.o.